Exec Who Jacked Up Price Of A Life-Saving Drug Is Arrested

Martin Shkreli, the former hedge fund manager vilified in nearly every corner of America for buying a pharmaceutical company and jacking up the price of a life-saving drug more than fiftyfold, was arrested Thursday on securities fraud charges unrelated to the furor.

The boyish-looking 32-year-old entrepreneur - an unapologetically aggressive businessman and relentlessly self-promoting figure who has called himself "the world's most eligible bachelor" on Twitter and recently plunged into the hip-hop world by buying an unreleased album by the Wu-Tang Clan - was taken into custody in a gray hoodie and awaited an appearance in federal court in Brooklyn.

He was charged in a seven-count indictment unconnected to the drug price hikes imposed by his company, Turing Pharmaceuticals. The charges instead involve his actions at another drug company, Retrophin, which he ran as CEO from 2012 to 2014.

The indictment said Shkrelia and others orchestrated three interrelated fraud schemes from 2009 to 2014. It said they fraudulently induced investors to sink their money into two separate funds and misappropriated Retrophin's assets to satisfy Shkreli's personal and professional debts.

Shkreli "engaged in multiple schemes to ensnare investors through a web of lies and deceit," U.S. Attorney Robert Capers said in a statement.